EnVVeno Medical Corporation (NASDAQ:NVNO) | WebDisclosure

Switch to English

10238	Sociétés
211363	Mots-clés
141296	Articles
111973	Communiqués

Accueil
Sociétés
EnVVeno Medical Corporation

COMMUNIQUÉ DE PRESSE

publié le 15/08/2025 à 15:21, il y a 8 mois 3 jours

enVVeno Medical to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
enVVeno Medical Corporation to present at Webull Financial Corporate Connect Webinar Series: Biotech/MedTech on August 21, 2025, with CEO Robert Berman discussing innovative treatment solutions for deep venous disease

Webinar EnVVeno Medical Corporation Bioprosthetic Solutions Deep Venous Disease Webull Financial
BRÈVE

publiée le 06/08/2025 à 14:35, il y a 8 mois 12 jours

VenoValve d'enVVeno Medical : une solution rentable pour les IVC sévères

EnVVeno Medical Insuffisance Veineuse Chronique Approbation De La FDA Économies Sur Les Coûts Des Soins De Santé Valve VenoValve
BRÈVE

publiée le 06/08/2025 à 14:35, il y a 8 mois 12 jours

EnVVeno Medical's VenoValve: A Cost-Effective Solution for Severe CVI

FDA Approval EnVVeno Medical VenoValve Chronic Venous Insufficiency Healthcare Cost Savings
COMMUNIQUÉ DE PRESSE

publié le 06/08/2025 à 14:30, il y a 8 mois 12 jours

Health Economic Study Shows That enVVeno Medical's VenoValve(R) Would be a Cost-Effective Treatment Option for Patients with Severe Chronic Venous Insufficiency
Preliminary findings show VenoValve as cost-effective & clinically beneficial for severe CVI. Webcast discussing results. Potential $5.9B annual healthcare savings. Study shows cost savings and clinical benefits

Webcast VenoValve Healthcare Savings CVI Cost-Effectiveness
BRÈVE

publiée le 04/08/2025 à 15:10, il y a 8 mois 14 jours

EnVVeno Medical Explores Potential Impact of Trump's CVI Diagnosis on Treatment Options

FDA Approval VenoValve CVI Diagnosis Trump Impact Healthcare Cost
BRÈVE

publiée le 04/08/2025 à 15:10, il y a 8 mois 14 jours

EnVVeno Medical étudie l'impact potentiel du diagnostic d'IVC de Trump sur les options de traitement.

Approbation De La FDA Valve VenoValve Diagnostic De L'IVC L'impact De Trump Coût Des Soins De Santé
COMMUNIQUÉ DE PRESSE

publié le 04/08/2025 à 15:05, il y a 8 mois 14 jours

enVVeno Medical Participates in a New Virtual Investor "What This Means" Segment to Discuss How President Trump's Recent CVI Diagnosis May Impact the Company
enVVeno Medical is developing the VenoValve as a potential treatment for Chronic Venous Insufficiency. FDA decision expected in 2H'2025

EnVVeno Medical VenoValve Chronic Venous Insufficiency FDA Decision Deep Venous Disease
BRÈVE

publiée le 01/08/2025 à 14:05, il y a 8 mois 17 jours

EnVVeno Medical Q2 2025 Financial Report and Corporate Update

EnVVeno Medical VenoValve Q2 2025 Results EnVVe Progress FDA Decision
BRÈVE

publiée le 01/08/2025 à 14:05, il y a 8 mois 17 jours

Rapport financier et mise à jour de l'entreprise d'enVVeno Medical pour le deuxième trimestre 2025

EnVVeno Medical Valve VenoValve Résultats Du Deuxième Trimestre 2025 Progrès EnVVe Décision De La FDA
COMMUNIQUÉ DE PRESSE

publié le 01/08/2025 à 14:00, il y a 8 mois 17 jours

enVVeno Medical Reports Second Quarter 2025 Financial Results and Provides Corporate Update
enVVeno Medical reports $3.8M cash burn & financial results for Q2 2025. Operations funded through Q3'2026 with sufficient cash. FDA decisions & clinical program progress on track

Financial Results EnVVeno Medical Cash Burn FDA Decisions Clinical Program Progress

Les Echos

Publié le 17/04/2026 à 20:30, il y a 1 jour 11 heures

ALTAREA - Déclaration d’opérations sur actions propres
Publié le 17/04/2026 à 19:00, il y a 1 jour 13 heures

Cegedim : Publication du Document d’Enregistrement Universel 2025
Publié le 17/04/2026 à 19:00, il y a 1 jour 13 heures

Cegedim: Release of its 2025 Universal Registration Document
Publié le 17/04/2026 à 17:45, il y a 1 jour 14 heures

Carrefour announces the sale of its minority stake in CarrefourSA in Turkey to Aydın
Publié le 17/04/2026 à 17:45, il y a 1 jour 14 heures

Carrefour annonce la cession de sa participation minoritaire dans CarrefourSA en Turquie à Aydın

Voir tout LES ECHOS COMFI WIRE

Accesswire

Publié le 18/04/2026 à 04:00, il y a 1 jour 4 heures

Formation Metals Responds to OTC Markets Request on Recent Promotional Activity
Publié le 18/04/2026 à 02:00, il y a 1 jour 6 heures

AI/ML Innovations Announces Completion of Share Issuance
Publié le 18/04/2026 à 01:35, il y a 1 jour 6 heures

Medicure Announces Resignation of President and Chief Operating Officer
Publié le 18/04/2026 à 01:00, il y a 1 jour 7 heures

Onco-Innovations Strengthens Executive Leadership with Appointment of Dr. Islam Mohamed as Chief Medical Officer and Stephen M. Novak as Chief of Research and Development
Publié le 18/04/2026 à 00:00, il y a 1 jour 8 heures

Redwood AI Announces Collaboration with Aidos Innovations, Aimed at Enhancing Public Safety Collaboration with B.C. Government, Canadian Federal and Local Law Enforcement Agencies to Tackle the Fentanyl Crisis in British Columbia

Voir tout ACCESSWIRE

EQS Group

Publié le 18/04/2026 à 00:05, il y a 1 jour 8 heures

ESCMID Global: Maternal RSV vaccination cuts infant hospitalisation risk by over 80%, major UKHSA study finds
Publié le 17/04/2026 à 21:39, il y a 1 jour 10 heures

Linedata Services: Mise à disposition du Document d’Enregistrement Universel 2025 incluant le Rapport Financier Annuel 2025
Publié le 17/04/2026 à 20:33, il y a 1 jour 11 heures

LLB General Meeting 2026 – Shareholders approve all proposals of the Board of Directors
Publié le 17/04/2026 à 19:35, il y a 1 jour 12 heures

Stabilisation Notice
Publié le 17/04/2026 à 19:30, il y a 1 jour 12 heures

KAP AG: REFINANCING CONCEPT AGREED; NEW SYNDICATED LOAN SECURES FLEXIBILITY FOR THE ONGOING TRANSFORMATION PROCESS